gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Article

Send article

Functional results following treatment of retinal vein occlusion with intravitreal Bevacizumab

Meeting Abstract

Search Medline for

  • Christiane Kneifel - Städt. Klinikum Dessau
  • L. Krause - Städt. Klinikum Dessau

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg47

doi: 10.3205/11rg47, urn:nbn:de:0183-11rg473

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2011/11rg47.shtml

Published: June 15, 2011

© 2011 Kneifel et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Background: The central retinal vein occlusion is one of the most frequent ocular vascular pathologies. Cardiovascular diseases are the most important risk factors. Vein occlusions are divided into ischemic and non-ischemic. Neovascular glaucoma is one of the most important complication that could be observed and that may lead to blindness in many of these eyes. Anticoagulation, haemodilution, lasercoagulation and kryocoagulation were treatment opportunities. Anti-VEGF treatment nowadays gives a new therapeutic approach in this diseases.

Methods: Report of the functional results of 30 eyes with central retinal vein occlusion treated with intravitreal Bevacizumab with a minimum follow-up of three months in the years 2009 up today. The mean numbers of injections were two (1–5 injections) during a mean follow-up of ten months.

Results: In 68% of eyes a better visual acuity and a decreased macular thickness in the OCT could be achieved following injection. A visual acuity of 0.5 and better was found in 48% of treated eyes.

Conclusion: Bevacizumab is a new therapeutical approach in the treatment of central retinal vein occlusion.